INSYS Therapeutics, Inc. was a big mover last session, as the company saw its shares rise more than 15% on the day. The move came on solid volume too with far more shares changing hands than in a normal session. This continues the recent uptrend for the company — as the stock is now up 57.1% in the past one-month time frame.

The move came after the FDA granted Fast Track designation to the company’s cannabidiol oral solution for treating Prader-Willi syndrome.

The company has not seen any estimate revisions in the past one month, while the Zacks Consensus Estimate for the current quarter has also remained unchanged. The recent price action is encouraging though, so make sure to keep a close watch on this firm in the near future.

INSYS Therapeutics currently has a Zacks Rank #3 (Hold), while its Earnings ESP is 0.00%.

Investors interested in the Medical – Products industry may consider Bio-Rad Laboratories, Inc. (BIO Quick QuoteBIO - Free Report) , which has a Zacks Rank #1 (Strong Buy). You can see the complete list of today’s Zacks #1 Rank stocks here.

Is INSY going up? Or down? Predict to see what others think: Up or Down

Wall Street’s Next Amazon

Zacks EVP Kevin Matras believes this familiar stock has only just begun its climb to become one of the greatest investments of all time. It’s a once-in-a-generation opportunity to invest in pure genius.

Click for details >>